See more : Biotage AB (publ) (BIOT.ST) Income Statement Analysis – Financial Results
Complete financial analysis of HTG Molecular Diagnostics, Inc. (HTGM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of HTG Molecular Diagnostics, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- freenet AG (FNTN.HM) Income Statement Analysis – Financial Results
- PT Armidian Karyatama Tbk (ARMY.JK) Income Statement Analysis – Financial Results
- Energiedienst Holding AG (0QOH.L) Income Statement Analysis – Financial Results
- Redde Northgate plc (REDD.L) Income Statement Analysis – Financial Results
- Grasim Industries Limited (GRSXY) Income Statement Analysis – Financial Results
HTG Molecular Diagnostics, Inc. (HTGM)
About HTG Molecular Diagnostics, Inc.
HTG Molecular Diagnostics, Inc. a life sciences company, focuses on the precision medicine. The company offers instruments; consumables comprising assay kits; and software that automate sample processing and profiles various molecular targets. Its marketed molecular profiling panels include HTG Transcriptome Panel; HTG EdgeSeq precision immuno-oncology panel; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL cell of origin assay EU; HTG EdgeSeq DLBCL cell of origin assay; HTG EdgeSeq Oncology Biomarker Panel; HTG EdgeSeq ALKPlus assay EU; HTG EdgeSeq Pan B-Cell Lymphoma Panel; HTG immune response panel; and HTG mouse mRNA tumor response panel. The company distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. HTG Molecular Diagnostics, Inc. has a governing agreement with QIAGEN Manchester Limited. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.37M | 8.91M | 8.55M | 19.20M | 21.50M | 14.76M | 5.13M | 4.04M | 3.33M | 2.24M | 2.48M |
| Cost of Revenue | 4.57M | 4.09M | 3.99M | 8.91M | 5.09M | 4.97M | 4.14M | 3.34M | 3.20M | 2.25M | 1.82M |
| Gross Profit | 1.79M | 4.81M | 4.56M | 10.29M | 16.41M | 9.79M | 996.85K | 706.06K | 124.04K | -3.83K | 664.63K |
| Gross Profit Ratio | 28.18% | 54.02% | 53.31% | 53.60% | 76.33% | 66.31% | 19.42% | 17.47% | 3.73% | -0.17% | 26.79% |
| Research & Development | 6.78M | 6.09M | 6.08M | 10.57M | 12.60M | 10.00M | 7.90M | 4.60M | 3.08M | 4.20M | 3.92M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 19.97M | 17.51M | 17.43M | 14.99M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 15.84M | 16.55M | 18.06M | 18.68M | 19.97M | 17.51M | 17.43M | 14.99M | 0.00 | 0.00 | 0.00 |
| Other Expenses | 8.33K | -1.03M | 22.27K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 9.90M | 7.71M | 7.29M |
| Operating Expenses | 22.62M | 22.64M | 24.14M | 29.25M | 32.57M | 27.51M | 25.33M | 19.60M | 12.97M | 11.91M | 11.21M |
| Cost & Expenses | 27.20M | 26.73M | 28.13M | 38.16M | 37.66M | 32.48M | 29.46M | 22.93M | 16.18M | 14.16M | 13.03M |
| Interest Income | 94.36K | 29.88K | 254.74K | 623.36K | 715.72K | 73.18K | 112.41K | 85.86K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 856.73K | 1.06M | 1.02M | 957.54K | 901.82K | 1.31M | 1.87M | 1.72M | 706.87K | 211.87K | 251.08K |
| Depreciation & Amortization | 689.83K | -1.74M | 1.62M | 2.36M | 1.47M | 1.24M | 1.47M | 662.56K | 496.60K | 315.09K | 222.63K |
| EBITDA | -20.14M | -19.56M | -17.96M | -16.60M | -14.08M | -16.41M | -22.69M | -19.01M | -12.75M | -11.24M | -12.30M |
| EBITDA Ratio | -316.35% | -219.60% | -210.11% | -86.45% | -65.48% | -111.17% | -442.03% | -470.25% | -383.15% | -501.21% | -495.81% |
| Operating Income | -20.83M | -17.82M | -19.59M | -18.96M | -16.16M | -17.72M | -24.33M | -18.89M | -12.85M | -11.92M | -10.55M |
| Operating Income Ratio | -327.19% | -200.11% | -229.10% | -98.73% | -75.15% | -120.08% | -474.04% | -467.39% | -385.97% | -531.21% | -425.21% |
| Total Other Income/Expenses | -754.04K | 701.13K | -1.27M | -334.18K | -291.16K | -1.23M | -1.70M | -2.50M | -1.11M | 146.05K | -2.23M |
| Income Before Tax | -21.58M | -17.12M | -20.86M | -19.29M | -16.45M | -18.96M | -26.03M | -21.39M | -13.96M | -11.77M | -12.77M |
| Income Before Tax Ratio | -339.03% | -192.24% | -243.96% | -100.47% | -76.50% | -128.44% | -507.13% | -529.19% | -419.30% | -524.70% | -514.91% |
| Income Tax Expense | 10.84K | 22.48K | 14.42K | 3.38K | 3.53K | 2.92K | 10.12K | 10.19K | -402.68K | 357.92K | -1.97M |
| Net Income | -21.59M | -17.15M | -20.87M | -19.30M | -16.45M | -18.96M | -26.04M | -21.40M | -13.96M | -11.77M | -12.77M |
| Net Income Ratio | -339.20% | -192.49% | -244.13% | -100.49% | -76.52% | -128.46% | -507.32% | -529.44% | -419.30% | -524.70% | -514.91% |
| EPS | -24.28 | -29.66 | -54.12 | -91.17 | -0.75 | -2.24 | -4.58 | -5.92 | -52.33 | -44.13 | -47.89 |
| EPS Diluted | -24.28 | -29.66 | -54.12 | -91.17 | -0.75 | -2.24 | -4.58 | -5.92 | -5.95 | -44.13 | -47.89 |
| Weighted Avg Shares Out | 889.28K | 578.01K | 385.66K | 211.66K | 22.02M | 8.48M | 5.69M | 3.61M | 266.72K | 266.72K | 266.72K |
| Weighted Avg Shares Out (Dil) | 889.28K | 578.01K | 385.66K | 211.66K | 22.02M | 8.48M | 5.69M | 3.61M | 2.35M | 266.72K | 266.72K |
HTG Molecular Diagnostics, Inc. (HTGM) CEO John Lubniewski on Q1 2022 Results - Earnings Call Transcript
HTG Molecular Diagnostics, Inc. (HTGM) Reports Q1 Loss, Lags Revenue Estimates
Trading Penny Stocks on April 7th? Fed News Causes Market Movement
HTG Molecular Diagnostics, Inc. (HTGM) CEO John Lubniewski on Q4 2021 Results - Earnings Call Transcript
HTG Molecular Diagnostics Stock (HTGM): Why The Price Surged Today
HTG Molecular Diagnostics' (HTGM) CEO John Lubniewski on Q3 2021 Results - Earnings Call Transcript
HTG Expands Therapeutics Team
HTG Molecular Diagnostics to Present at H.C. Wainwright's 23rd Annual Global Investment Conference
HTG Molecular Diagnostics, Inc. (HTGM) CEO John Lubniewski on Q2 2021 Results - Earnings Call Transcript
HTG Molecular Diagnostics Reports Second Quarter 2021 Results
Source: https://incomestatements.info
Category: Stock Reports